ABT Stock Recent News

Abbott Laboratories is one of the smaller holdings in my portfolio, but that won't be the case for much longer. Strength throughout the base business powered the company's sales higher in the first quarter. ABT's interest coverage ratio approached 25 in the most recent quarter, which supports an AA- credit rating from S&P.

Fund managers have historically pivoted to top dividend stocks in low-interest-rate environments. With the Fed poised to start cutting interest rates within the next eight to 12 months, these two blue chip dividend stocks could be compelling buys.

If you want your portfolio to pay you cash like clockwork, it's time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.

Healthcare stocks certainly haven't set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

Apple and Abbott Laboratories are facing multiple issues. However, both have excellent track records and important growth avenues.

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.